228 related articles for article (PubMed ID: 11140883)
1. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
Leshem B; Vourka-Karussis U; Slavin S
Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice.
Vourka-Karussis U; Karussis D; Ackerstein A; Slavin S
Exp Hematol; 1995 Mar; 23(3):196-201. PubMed ID: 7875238
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
5. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
Weiss L; Nusair S; Reich S; Sidi H; Slavin S
Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
8. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
9. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
Weiss L; Reich S; Slavin S
Cancer Invest; 1992; 10(1):19-26. PubMed ID: 1735011
[TBL] [Abstract][Full Text] [Related]
10. Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma.
Truitt RL; Shih CC; LeFever AV
Transplantation; 1986 Mar; 41(3):301-10. PubMed ID: 3513389
[TBL] [Abstract][Full Text] [Related]
11. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease.
Yoshida R; Yamana H; Hayashi M; Yasuda E; Shibayama Y; Hirose Y; Tanigawa N; Uchiyama K; Kubota T
J Interferon Cytokine Res; 2021 Sep; 41(9):310-318. PubMed ID: 34543129
[TBL] [Abstract][Full Text] [Related]
13. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
[TBL] [Abstract][Full Text] [Related]
15. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.
Boyer MW; Vallera DA; Taylor PA; Gray GS; Katsanis E; Gorden K; Orchard PJ; Blazar BR
Blood; 1997 May; 89(9):3477-85. PubMed ID: 9129056
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
17. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia.
Weiss L; Weigensberg M; Morecki S; Bar S; Cobbold S; Waldmann H; Slavin S
Cancer Immunol Immunother; 1990; 31(4):236-42. PubMed ID: 2379219
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
Reddy P; Teshima T; Hildebrandt G; Duffner U; Maeda Y; Cooke KR; Ferrara JL
Blood; 2002 Nov; 100(9):3429-31. PubMed ID: 12384449
[TBL] [Abstract][Full Text] [Related]
19. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
20. Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation.
Meredith RF; Okunewick JP
Transplantation; 1983 Apr; 35(4):378-85. PubMed ID: 6340292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
